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Measurement of urinary excretion of xanthurenic acid after administration of 
an oral dose of tryptophan has been the technique most widely used for detection 
of subclinical pyridoxine deficiency. Although alterations in urinary excretion of 
this and other metabolites of tryptophan have been described in a wide variety of 
conditions and diseases,’ comparison of results obtained by different investigators 
has been difficult because of variability in dose and kind of tryptophan, urine 
collections, method of analysis and definitions of “abnormality.” Recently, as 
a result of the development of more accurate methods by Price and associates2 
and the plea for standardization made by C o ~ r s i n , ~  greater agreement has been 
reached concerning proper methods of study. 
For the past ten years our laboratory has been concerned with the investigation 
of the prevalence of biochemical evidence of deficiency of several of the water- 
soluble vitamins in il l  patients in our hospital. Several years ago we began to 
assess the relative “sensitivity” of several methods proposed for the detection of 
pyridoxine deficiency in normal adults placed upon a pyridoxine-deficient diet 
supplemented with vitamin-free casein. Studies included serial determinations 
of absolute lymphocyte count, serum and erythrocyte glutamic-oxalacetic trans- 
nminase and glutamic-pyruvic transaminase, taurine excretion after a cysteine 
load, estimation of phosphorylated and nonphosphorylated derivatives of pyri- 
doxine in plasma, urinary excretion of 4-pyridoxic acid and 24-hour urinary 
excretion of xanthurenic acid and hydroxykynurenine after a 5 g dose of L- 
tryptophan. Afte’r the study of three patients, we arrived at the same conclusions 
as those in the then just published papers of Yess, Swan and co l leagi ie~~-~  that
the earliest and most consistent abnormalities observed were increases in ex- 
cretion of hydroxykynurenine and xanthurenic acid after a tryptophan load. 
At this time, Coursin made his plea for standardization of methods and for 
utilization of a 2 g dose of ~- t ryptophan .~  For this reason and also because we 
had observed considerable interindividual variation in excretion of tryptophan 
metabolites in our normal subjects tested during control periods before and after 
the period of deficiency, a comparison of the 2 g and 5 g dose of L-tryptophan 
was made in sixteen healthy adults both prior to and following administration of 
pyridoxine.’ Urinary hydroxyanthranilic acid was also determined, since the 
ratio of excretion of hydroxyknurenine to that of hydroxyanthranilic acid has 
been proposed as a helpful adjunct in the assessment of pyridoxine deficiency.8 
In order to clarify the rationale for this approach, FIGURE 1 presents a diagram 
of the metabolic pathway of tryptophan metabolism of importance in the trypto- 
phan load test. Tryptophan pyrrolase, which catalyzes the first reaction in this 
pathway, is inducible by substrate (tryptophan) and by adrenocortical steroids. 
The vitamin B6-containing enzymes are not subject to adaptive change (enzyme 
induction),9 and therefore a relative or absolute decrease in activity of these 
enzymes could bring about alterations in tryptophan metabolism. Since the 
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FIGURE 1. Abbreviated outline of pathway of tryptophan metabolism of importance in 
the tryptophan load test for pyridoxine deficiency. 
increase in excretion of kynurenic acid in pyridoxine-deficient animals and 
humans is of a lesser magnitude than the increase in xanthurenic acid (XA), 
kynurenine transaminase may be decreased to a greater extent by vitamin Bs 
deficiency than hydroxykynurenine transaminase.1° Several alternative explana- 
tions have been offered for the somewhat paradoxical increase in xanthurenic 
acid in pyridoxine-deficient animals and humans. Although the activity of hy- 
droxykynurenine transaminase in the soluble supernatant fraction of tissue is 
decreased markedly, a major fraction of hydroxykynurenine transaminase 
activity is mitochondria1 in origin and is only slightly decreased by pyridoxine 
deficiency.I1 On the other hand, Korbitz and colleagues1° have proposed that 
an alternate, non-B6-dependent pathway may be responsible for increases in 
xanthurenic acid excretion. If a significant “block” in metabolism of hydroxy- 
kynurenine (HK)  in pyridoxine deficiency were brought about by a decrease 
in activity of hydroxykynureninase, then one might also expect a decrease in 
formation of hydroxyanthranilic acid (HAA) and an increase in the HK/HAA 
ratio. 
Our findings after administration of 2 g and 5 g doses of L-tryptophan 
to normal subjects provided data in support of Coursin’s recommendation. 
After a 5 g dose of tryptophan, individual variability in excretion of these 
metabolites was so great that “tolerance limits” for range of excretion of them 
in a population of normal subjects were too broad to be meaningful. In addition, 
when effects of administration of the 2 g and 5 g doses of tryptophan were cow- 
pared in the same subjects, the larger dose brought about a several-fold rise in 
percent of load excreted as XA (0.62% ) and HK (0.5 1 % ), but percent of dose 
excreted as HAA (0.44%) had decreased. After the 2 g load, the values were 
XA 0.35%, HK (male) 0.14% HK (female) 0.28%, and HAA 0.71%. These 
differences have been interpreted as probably resulting from induction of higher 
tryptophan pyrrolase activity by the larger dose of substrate; the percent of dose 
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of tryptophan excreted as HAA was thought to be decreased with the larger 
dose because hydroxykynureninase, which does not increase adaptively, does not, 
under normal conditions, have sufficient activity to catalyze the conversion of the 
greatly increased amounts of HK to HAA. 
In these same subjects, when the 2 g of tryptophan load was repeated after 
administration of 62.5 mg of pyridoxine hydrochloride in divided doses, percent 
of dose excreted as HAA was doubled (1.47% ).  These findings demonstrate that 
hydroxykynureninase can increase in activity, even in normal individuals, if 
more vitamin is available for formation of coenzyme. Significant decreases in 
percent of the 5 g dose excreted as XA (0.27% ) and HK (0.16% ) after vitamin 
Be supplementation can be explained by the same mechanism. 
On the basis of these findings, we have concluded that in those prior studies 
utilizing doses of L-tryptophan much greater than 2 g, no statistical criteria for 
normality or abnormality can be established. Since many previous studies in 
which abnormalities have been reported in patients with a wide variety of dis- 
eases were conducted with larger doses of tryptophan, racemic mixtures and 
less reliable methods of analysis, we have attempted to reassess the validity of the 
tryptophan load test, with the standards recommended by Price and coworkers2 
and C o ~ r s i n , ~  in the screening of selected hospitalized patients for possible 
subclinical pyridoxine deficiency. 
Methods 
The following groups of subjects were selected for study: 
1. Patients with nutritional problems of gastroenteric origin. 
2. Patients with advanced atherosclerotic cardiovascular disease. 
3. Patients with malignant neoplasms: 
a. Subgroup with nonmetastatic cancer, 
b. Subgroup with metastases. 
Included in addition for comparison were a group of patients with normal 
nutrition hospitalized for management of diseases of lesser severity (chronic 
venous insufficiency, obesity, pilonidal sinus, etc.) , also patients with cancer who 
had been receiving supplemental vitamins and several subjects being treated with 
steroid hormones. 
All patients were assessed with respect to height, weight, history of recent 
weight loss and recent dietary and drug history. None had porphyria, scleroderma, 
rheumatoid arthritis, schizophrenia, tropical or nontropical sprue, carcinoma of 
the urinary bladder, Hodgkin's disease or leukemia. None were pregnant or 
receiving oral contraceptives. Any patients receiving drugs thought to have an 
influence on tryptophan metabolism or to interfere with the analytic procedure 
(soluble sulfonamides, procaine, para-amino-salicylic acid, acetophenetidin, di- 
phenylhydantoin, para-aminobenzoic acid, or isoniazid) were excluded. 
Two grams of L-tryptophan were given preprandially in gelatin capsules. 
Twenty-four hour acidified urine specimens were collected in dark bottles kept 
under refrigeration, Analyses for xanthurenic acid, hydroxykynurenine and 4- 
pyridoxic acid were performed by methods recently summarized by Price, Brown 
and Yew2 Similar to the experience of these authors, in several samples no 
HK or added standard was recovered. Determination of hydroxyanthranilic acid 
was by the method of Tompsett.12 The Aminco-Bowman spectrophotofluorometer 
was utilized for spectrofluormetric analyses, and the Beckman-DU spectrophoto- 
meter for spectrophotometric readings. 
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Determinations of excretion of 4-pyridoxic acid (4-PA) were used as a 
measure of recent dietary intake of vitamin and to detect possible vitamin SUP- 
plementation of which the patient himself was unaware. Any patient with 24-hour 
excretion of 6.5 micromoles or more of 4-PA was arbitrarily excluded. 
From the data obtained from our prior studies of normal adults, tolerance 
limitsI3 were calculated for the range of values to be expected in 99% of a 
similar population with 99% confidence (P = 0.99: gamma = 0.99). Utilizing 
these statistical criteria, the upper limits for “normality” in 24-hour excretion of 
metabolites after a 2 g load of tryptophan were: XA, 70 micromoles; HK (males), 
58 micromoles; HK (females), 83 micromoles, and HAA, 137 micromoles. 
Tolerance limits were too broad to define lower limits for excretion of these 
metabolites. 
Results 
TABLE 1 presents a summary of the abnormalities detected in the several 
groups of subjects who have been studied. All patients with increased excretion 
of XA (Column 1 ) had increases in excretion of HK as well (with the exception 
of one in whom no recovery of HK was obtained). Column 2 lists the numbers 
of additional patients who, according to our calculated tolerance limits, had 
normal levels of excretion of xanthurenic acid but increased values for HK. In 
our normal subjects the mean excretion of HK was significantly lower in males 
than in females, and therefore separate limits for each sex were estimated. How- 
ever, since Price and collaborators2 have reported a higher mean value for males 
and have not found a significant difference between values for excretion of HK 
TABLE 1 
ABNORMALITIES IN THE EXCRETION F XANTHURENIC (XA) AND HYDROXKYNURENINE (HK) 
IN VARIOUS CATEGORIES OF SUBJECTS 




Column 1 Column 2 Column 3. 
- XA 5 70 XA L- 70 
Number of XA > 70 HK HK > 83 
Subjects (micromoles/ Male: > 58 (micromoles/ 




Nutritionally normal patients 1 1  0 0 0 
Patients with gastroenteric 
disease 14 0 1 1 
Patients with atherosclerotic 
cardiovascular disease 21 1 2 0 
Patients with localized 
cancer 15 0 3 2 
Patients with metastatic 
cancer 16 4 4 3 
Patients with cancer 
receiving vitamin B. 9 0 4 3 
Patients receiving steroid 
hormones 8 5 3 3 
Column 3 is a retabulation of the number of patients with abnormalities in HK excretion 
listed in Column 2 with exclusion of those males with levels of HK excretion between 59 and 
83 micromoles per 24 hours. The number of subjects in each group with abnormalities is a 
sum of Columns 1 and 2 or 1 and 3 (depending on the criteria selected). 
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in males and females, the tolerance limit for males, established on the basis of 
our data, may be too low. For this reason, Column 3 is a retabulation of ab- 
normalities in HK excretion based upon the higher tolerance limit for females 
(83 micromoles/24 hours). This limit would appear to be more compatible with 
the range of values for normals reported by Price and associates.2 
A small group of "nutritionally normal" patients hospitalized for treatment 
of diseases of recent onset and of lesser severity were included as a check of the 
validity of the tolerance limits calculated for "normals." No abnormality in ex- 
cretion of tryptophan metabolites was detected in these subjects. 
Patients with gastroenterologic problems known to entail possible nutritional 
abnbrmalities were also screened. These subjects had cirrhosis of the liver or 
were patients with longstanding weight loss following operative removal of 
portions of the stomach or intestinal tract. Although the highest frequency of 
relatively low values for 4-pyridoxic acid excretion ( 1.5 micromoles or less) 
was found in this group (six of 13 subjects), none displayed an elevated excre- 
tion of XA, and only one had an increase in urinary HK. 
The demonstration by Rinehart and Greenberg14 that monkeys on a pyridoxine- 
deficient diet develop arterial lesions resembling atherosclerosis in man prompted 
the inclusion of a group of patients with severe atherosclerotic cardiovascular 
disease. Abnormalities were found after the tryptophan load test in three of 2 1 
subjects and, of these, two male patients had only a slight elevation in excretion 
of HK. The third subject with definite abnormalities in excretion of both XA and 
HK was acutely ill with ischemia of one leg secondary to a femoral arterial 
embolus, presumably arising from the heart following a recent myocardial 
infarct. 
The group of patients with malignant neoplasms was subdivided into 
those individuals without metastatic disease and those with clinical or roentgeno- 
logic evidence of dissemination of tumor. This was an attempt at differentiation 
according to severity of disease and by selection, within the latter category, of 
those subjects most likely to be in negative nitrogen balance. As a reflection of 
these differences, mean weight loss in the group of patients with metastatic 
cancer was 22 pounds as opposed to 3% pounds in the subjects without evidence 
of metastasis. Since many patients with extensive neoplasms were receiving 
vitamins at the time they were first encountered, a small group of these patients 
were also tested and are reported separately. 
A special effort was made to test as a separate group patients receiving 
steroid therapy, since changing levels of steroid hormones have been shown to 
influence tryptophan metabolism and are thought to act as an important variable 
affecting results of the tryptophan load test in ill subjects.15 
TABLE 2 is a tabulation of the values obtained in patients with elevated ex- 
cretion of XA (steroid-treated group not included). The four subjects with 
metastatic cancer had relatively low values for excretion of 4-PA. Excretion of 
HAA was within normal limits in all. The mean value for excretion of HAA in 
normal subjects with 70 +- 13 micromoles/24 hours. 
TARLE 3 lists the results obtained in those subjects who had increased levels 
of HK in the urine but normal values for XA. Excretion of 4-PA and HAA was 
highly variable. Of interest is that four of nine patients with cancer receiving 
supplemental pyriodoxine for at least three days in doses varying from 2 mg to 
50 mg per day excreted HK in amounts above 99% tolerance limits for normal. 
The four patients who did display abnormalities in HK excretion, however, 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2 0 3 r si a c3 w 4 
38 Annals New York Academy of Sciences 
TABLE 4 records the results obtained after administration of the tryptophan 
load to patients being treated with either adrenocortical steroids, stilbestrol, or 
an androgen. The three patients receiving adrenal corticoids who had normal 
values for XA had all been on steroid therapy for months, while the three with 
elevated values for this metabolite had received the steroid for much shorter 
periods. This possible relationship between duration of administration and level 
of XA excretion did not hold, however, for the subjects receiving estrogen or 
androgen, since all had been receiving these medications for a prolonged period. 
In each group of subjects (with the exception of vitamin- and steroid-treated 
groups), statistical analysis of mean values in individuals not displaying one of 
the above abnormalities has been performed. Although, as expected, the variance 
was greater than that reported for normal controls, no significant difference 
between group means was found. Fourteen subjects, scattered throughout the 
various groups, had levels of excretion of 4-PA at or below 1.5 micromoles/24 
hours, while values for XA and HK were normal. Calculations of ratio of excre- 
tion of HK to that of HAA were not of interpretive value, since excretion of 
HAA was highly variable and increases in HK were not accompanied by any 
predictable or characteristic change in excretion of HAA. Mean level of excretion 
of HAA was not significantly decreased in patients with increased excretion of 
XA or HK. 
Discussion 
Several factors complicate the interpretation of the significance of deviations 
from “normality” in excretion of the several metabolites of tryptophan after a 
tryptophan load is administered to hospitalized patients. The ‘‘stress” of the 
primary illness brings about an increase in secretion of glucocorticoids by the 
adrenals. Increased amounts of adrenal corticosteroids stimulate adaptive in- 
creases in activity of tryptophan pyrrolase in animals and man.9J5 Altman and 
GreengardI5 have reported that hydrocortisone causes a two- to fourfold increase 
in level of activity of tryptophan pyrrolase in human liver and that the level 
of activity of this enzyme is linearly related to level of urinary excretion of 
kynurenine after a 2 g dose of L-tryptophan. An increase in activity of tryptophan 
pyrrolase brings about shunting of a larger fraction of free tryptophan via the 
kynurenine pathway, resulting in increased excretion of kynurenine and hydro- 
xykynurenine and other related metabolites. Altman and Greengard propose that 
adaptive increases in activity of tryptophan pyrrolase induced by adrenocortical 
hormones may be the common factor leading to increased excretion of these 
metabolites in humans with various diseases. 
In a nutritionally normal subject with elevated activity of tryptophan pyrrolase 
and increased urinary excretion of kynurenine (after a tryptophan load) brought. 
about by administration of hydrocortisone, administration of pyridoxine was 
followed by a return of excretion of urinary kynurenine to normal values, while 
tryptophan pyrrolase remained e1e~ated.l~ Since vitamin Be-containing coen- 
zymes are not normally present at saturation levels, enzyme activity (kynurenin- 
ase, hydroxykynureninase, etc.) is increased when this vitamin is provided in 
greater amounts. Since this phenomenon is demonstrable in nutritionally normal 
s ~ b j e c t s , ~ J ~  one cannot assume that correction of an abnormality in urinary 
content of these metabolites after administration of pyridoxine is de facto evi- 
dence of a pre-existing deficiency unless one accepts the premise that anything 
less than maximal activity of these pyridoxal-containing enzymes represents a 
clinically significant deficiency. 
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The mechanism by which sex hormones influence tryptophan metabolism has 
not yet been defined. Elevated excretion of xanthurenic acid, kynurenine, 
hydroxykynurenine and other metabolites has been observed in pregnant women” 
and in women receiving oral contraceptives.*8 To our knowledge, the similar 
pattern observed in our patient receiving norethandrolone has not been previously 
reported in man. In an isolated experiment, Schor and FriedenI9 have reported 
that administration of testosterone to  rats is followed by a twofold increase in 
activity of tryptophan pyrrolase. In support of the possible role of androgens in 
enzyme induction is the recent demonstration that several drug-metabolizing 
enzymes increase in activity after administration of 19-nortestosterone deriva- 
tives to mice.20 Norethynodrel, a component in an oral contraceptive, is also a 
19-norsteroid and has been shown to have an effect similar to that of nor- 
ethandrolone in another system2’ However, estrogenic substances, as well as 
androgens and progestational agents, may also have an influence, since stilbestrol, 
which has been shown to induce the formation of a new protein in male chickens, 
might also act to stimulate synthesis of apoenzyme.2% In addition, the influence 
of one steroid upon the metabolism of another steroid has not yet been fully 
clarified. Since several androgenic steroids have been shown to inhibit the de- 
gradation of cortisol, increasing its plasma half-life and decreasing its turnover 
rate,23#24 i t  is possible that androgens may influence tryptophan metabolism 
through their effect upon metabolism of cortisol. 
Another major variable affecting results obtained with the tryptophan load test 
is the subject’s level of protein intake and general state of protein metabolism. 
Both influence the amount of free tryptophan available for metabolism via the 
kynurenine pathway. In addition, increases in amount of free tryptophan bring 
about adaptive increases (induction by substrate) in tryptophan pyrrolase activity 
and further shunting of tryptophan into this pathway. Tryptophan pyrrolase 
activity is higher in rats on a high-protein diet.y The higher the protein intake, 
the greater the excretion of tryptophan metabolites in experimental subjects 
receiving a pyridoxine-deficient diet.6 On the other hand, increased catabolism 
of endogenous protein and negative nitrogen balance are also associated with in- 
creased levels of free tryptophan and increased activity of tryptophan pyrrolase. 
Wood, Rivlin and KnoxZ5 have shown that tryptophan pyrrolase activity in- 
creases in mice in the terminal phases of cancer as protein catabolism increases. 
As Knox9 has recently pointed out, in some instances at  least, it may be the 
discrepancy between a high induced level of tryptophan pyrrolase and the level 
of the nonadapting kynureninase and hydroxykynureninase that permits the ac- 
cumulation of metabolites of kynurenine in the urine. In other words, the ob- 
served “block” in metabolism, thought to be caused by pyridoxine deficiency, is, 
in a sense, caused by the dose of tryptophan used in the test and the additional 
free tryptophan arising from dietary and endogenous sources. In support of the 
role played by tryptophan in substrate induction of tryptophan pyrrolase in man 
is the recent demonstration by Hankes, Brown and associates,26 utilizing 14C- 
labeled tryptophan in man, that simultaneous administration of a 2 g load of 
L-tryptophan produces a two- to fourfold increase in urinary radioactivity in 
kynurenine and hydroxykynurenine and xanthurenic acid: they explain their 
findings on this basis. 
Another variable, about which we are still not fully knowledgeable, is the 
influence of certain drugs upon the performance of the test. Price and colleagues’ 
have shown that some agents interfere with the analytic technique itself. The  
mechanism of action of other drugs such as diphenylhydantoin has not yet been 
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explained; we, too, have noted abnormalities in hydroxykynurenine excretion in 
several patients (not included in this study) who were receiving this compound. 
Canal and Maffei-Faccioli27 have reported that reserpine causes an increase in 
tryptophan pyrrolase activity which is not adrenal-dependent. Perhaps other 
drugs have a similar effect. 
The current techniques that we have utilized for measurement of tryptophan 
metabolites and 4-pyridoxic acid, although accurate and apparently specific 
(provided certain drugs are excluded), are laborious and would not be easily 
adaptable to performance in a routine laboratory for clinical biochemistry. Since 
these procedures are very time-consuming, no attempt has been made to study 
a segment of the hospital population as a whole. The groups of patients subjected 
to this preliminary screening were selected for specific reasons. The “nutritionally 
normal” patients were studied to provide one “internal control.” In addition, after 
this investigation was in progress, it became apparent that solitary abnormalities 
in excretion of hydroxykynurenine would be particularly difficult to interpret. 
For this reason, patients with neoplasms who were receiving vitamins were 
selected as another group that might be useful for comparison. The frequent 
finding of elevated HK excretion in this group of vitamin-supplemented patients 
with cancer could result from incomplete correction of a pre-existing deficiency 
of pyridoxine or could be interpreted in support of the premise that other 
variables that affect tryptophan metabolism may be primarily responsible for 
this abnormality. 
The influence of steroids, particularly adrenocorticoids, has been investigated 
to demonstrate that a major variable that may influence results and their interpre- 
tation may be the effect of the “stress” of the primary illness or of measures used 
in its treatment upon adrenocortical hormonal secretion. 
The very low incidence, almost total absence, of abnormalities detectable in 
patients with “nutritional diseases” may be related to errors in selection of pa- 
tients or, perhaps more likely, to the combination of a relatively low protein 
intake in a group of patients with longstanding illnesses in which the stress of 
acute disease and its accompanying adrenocortical hypersecretion are absent. 
The rarity of detectible abnormalities in excretion of hydroxykynurenine or 
XA in patients with atherosclerotic cardiovascular disease by no means excludes 
a possible relationship between subclinical pyridoxine deficiency and the de- 
velopment of atherosclerotic disease in man but does demonstrate that this 
particular methodologic approach is unsatisfactory for demonstrating any such 
relation. 
The absence of significant increases in xanthurenic acid in patients with 
nonmetastatic neoplastic disease, the infrequent occurrence of increased ex- 
cretion of HK and the appearance of increased amounts of HK in the urine of 
four of nine vitamin-supplemented patients with cancer complicate interpreta- 
tion of the significance of elevated levels of HK alone. One patient with non- 
metastatic cancer had increases in HK that might be termed “borderline,” while 
in another, increased excretion of HK was accompanied by simultaneous in- 
creases in HAA.  The higher prevalence of abnormalities in patients with metasta- 
tic cancer could be secondary to a higher freqeuncy of deficiency of vitamin Bs 
in more debilitated patients. However, it could also be related to the effect of 
greater “stress” of the primary disease. resulting in more protein catabolism, in- 
creased secretion of adrenal corticoids. and induction of tryptophan pyrrolase, 
with “funneling” of considerably greater amounts of tryptophan through the 
“kynureninase pathway.” Actually all three factors (decreased amounts of 
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vitamin, increased protein catabolism, and adaptive increases in tryptophan 
pyrrolase) could be acting in concert. 
The interpretation of the tryptophan load test in hospitalized patients is 
complicated by our inability to weigh accurately the influence of these multiple 
and sometimes conflicting variables on excretion of metabolites of tryptophan. 
Either a high protein intake or, conversely, a profound negative nitrogen balance 
could bring about “abnormal” increases in excretion of several metabolites 
of tryptophan that might not have occurred had neither of these variables been 
present. In their absence, the activity of kynureninase and related enzymes might 
have been adequate to handle a lesser “load” of free tryptophan. On the other 
hand, i t  is quite possible that more abnormalities might have been detected in 
some of our more il l  patients had they not been ingesting a diet relatively low in 
protein. In addition, although an attempt has been made to exclude those patients 
receiving drugs that Price, Brown and Yess‘ have shown may interfere in the 
analytical procedures for several of these metabolites, other drugs, about which 
we are still unaware, might also interfere. 
The absence of a significant decrease in level of excretion of HAA poses the 
question raised by Knox of whether the tryptophan load itself is primarily re- 
sponsible for the production of observed abnormalities, or whether a decrease 
in the functional adequacy of the kynureninase pathway is of practical signifi- 
cance. HernandezzR has shown that after administration of a tryptophan load t o  
pregnant women, the increase in excretion of xanthurenic acid is accompanied 
by sirhultaneous increases in HAA and N1methylnicotinamide. Excretion of the 
latter product did not differ significantly in those women with high or  with low 
XA excretion. Increased excretion of niacin metabolites in pregnant women has 
also been reported by Brown and  coworker^.^^ Brown and others2Y have recently 
presented further data concerning elevated quinolinic acid excretion in experi- 
mental pyridoxine deficiency and have discussed the still unresolved problem 
of the role of vitamin B6 in niacin synthesis. 
In normal subjects studied under carefully controlled conditions, statistical 
criteria ciin be used to define “abnormality.” As has been pointed out, this is 
much more difficult when the tryptophan load test is used for screening for these 
“abnormalities” in hospitalized patients in whom, for practical reasons, some 
other influential variables cannot be controlled. This does not mean that the ab- 
normalities in excretion of tryptophan metabolites observed in some of these 
patients might not have been secondary to decreases in activity of vitamin 
B6-containing enzymes. Unfortunately, however, the demonstration that these 
abnormalities are correctable by pyridoxine cannot be used as presumptive 
evidence of a significant pre-existing pyridoxine deficiency. At our  present state 
of knowledge, there is no clinical condition or histopathologic lesion that can be  
used to correlate with and confirm the significance of these biochemical abnormal- 
ities. Rare clinical entities such as pyridoxine-responsive anemia30 and the 
pyridoxine-dependency syndromez1 appear to be secondary to inborn errors in 
normal utilization of pyridoxine, since extremely large quantities of vitamin are  
usually needed for correction of the clinical manifestations. In the absence of 
clinical-anatomic correlates serving to define “deficiency” with respect to some 
of the other vitamins, a “post hoc” type of reasoning has been utilized in some 
instances to define “subclinical deficiency” of pyridoxine when certain ab- 
normalities in urinary excretion of tryptophan metabolites appear after a trypto- 
phan load. The whole concept of “subclinical deficiency” of a vitamin is still in 
limbo and will remain so until one can demonstrate that that subclinical de- 
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ficiency is interfering with the “optimal” health of the individual. Determina- 
tions of erythrocyte transketolase activity may be used to  follow the whole 
spectrum of thiamine deficiency of varying severity, culminating in the demon- 
stration of most extreme abnormalities in Wernicke’s disease,”2 In this instance, 
there is more presumptive evidence that this abnormality is specific for thiamine 
deficiency and that lesser decreases in activity of thiamine-containing enzymes 
might have a deleterious effect upon carbohydrate metabolism. On the other 
hand, for example, there is as yet no definitive evidence that the many people 
with blood and buffy coat ascorbic acid values far below levels compatible with 
tissue saturation are  in less satisfactory physical condition or are less able to re- 
cover from an illness than persons having very high blood and tissue levels in this 
vitamin. Such considerations are particularly pertinent with respect to pyri- 
doxine, a vitamin quite ubiquitous in dietary distribution. Assessment of the 
adequacy of vitamin Bs nutriture may require the development of other tech- 
niques more specific than those currently available. Direct measurement of 
vitamin Be in blood would be desirable, but many difficulties have been en- 
countered with currently available enzymatic, microbiological and chemical 
methods. The presence of the vitamin in phosphorylated and protein-bound 
complexes requires the development of more satisfactory procedures for pre- 
liminary extraction of the vitamin before this approach can be successfully 
utilized.33 
Sutnmary 
The tryptophan load test has been administered to  selected groups of hospital- 
ized patients. Twenty-four hour urinary levels of xanthurenic acid or hydroxy- 
kynurenine above 99% tolerance limits for “normals” were most frequently 
observed in patients with extensive cancer. Several alternative explanations for 
the appearance of these abnormalities, other than the presence of a subclinical 
pyridoxine deficiency, are discussed. In view of the possible lack of specificity 
of the “tryptophan load test,” when utilized for the detection of pyridoxine de- 
ficiency in ill patients, considerable caution is required in interpretation of results 
obtained. Further investigation, with the development of other approaches to  
diagnosis, will be necessary before the prevalence and practical significance of 
deficiency of vitamin Ba in ill adults can be assessed. 
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